Onward Medical N.V. (ONWD.BR)
EUR 4.74
(-0.21%)
EUR 4.74
(-0.21%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -36.18 Million EUR | -10.4% |
| 2022 | -32.77 Million EUR | 4.49% |
| 2021 | -34.31 Million EUR | -71.45% |
| 2020 | -20.01 Million EUR | -48.44% |
| 2019 | -13.48 Million EUR | -36.03% |
| 2018 | -9.91 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -9.12 Million EUR | -8.01% |
| 2024 Q2 | -9.12 Million EUR | 0.0% |
| 2023 Q1 | -9.64 Million EUR | 42.53% |
| 2023 FY | -36.18 Million EUR | -10.4% |
| 2023 Q4 | -8.44 Million EUR | 0.11% |
| 2023 Q3 | -8.45 Million EUR | 56.13% |
| 2023 Q2 | -19.28 Million EUR | -100.0% |
| 2022 Q1 | -7.99 Million EUR | 25.75% |
| 2022 Q3 | -8.38 Million EUR | 47.56% |
| 2022 Q4 | -16.77 Million EUR | -100.0% |
| 2022 Q2 | -15.99 Million EUR | -100.0% |
| 2022 FY | -32.77 Million EUR | 4.49% |
| 2021 Q1 | -6.38 Million EUR | -13.93% |
| 2021 FY | -34.31 Million EUR | -71.45% |
| 2021 Q4 | -10.77 Million EUR | 0.0% |
| 2021 Q3 | -10.77 Million EUR | -68.69% |
| 2021 Q2 | -6.38 Million EUR | 0.0% |
| 2020 Q2 | -4.4 Million EUR | 0.0% |
| 2020 Q3 | -5.6 Million EUR | -27.33% |
| 2020 Q1 | -4.4 Million EUR | 0.0% |
| 2020 FY | -20.01 Million EUR | -48.44% |
| 2020 Q4 | -5.6 Million EUR | 0.0% |
| 2019 FY | -13.48 Million EUR | -36.03% |
| 2018 FY | -9.91 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -928.454% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 75.51% |
| Adocia SA | -21.16 Million EUR | -70.972% |
| Aelis Farma SA | -5.07 Million EUR | -612.505% |
| Biophytis S.A. | -17.02 Million EUR | -112.504% |
| Advicenne S.A. | -7.03 Million EUR | -414.593% |
| genOway Société anonyme | 1.56 Million EUR | 2408.087% |
| IntegraGen SA | -171.39 Thousand EUR | -21009.225% |
| Medesis Pharma S.A. | -3.95 Million EUR | -813.779% |
| Neovacs S.A. | -8.74 Million EUR | -313.807% |
| NFL Biosciences SA | -3.74 Million EUR | -865.992% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 45800.969% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -1041.016% |
| Sensorion SA | -22.06 Million EUR | -63.986% |
| Theranexus Société Anonyme | -6.82 Million EUR | -429.895% |
| TME Pharma N.V. | -6.73 Million EUR | -437.129% |
| Valbiotis SA | -7.36 Million EUR | -391.056% |
| TheraVet SA | -1.57 Million EUR | -2203.485% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -77.846% |
| argenx SE | -272.91 Million EUR | 86.743% |
| BioSenic S.A. | -28.77 Million EUR | -25.725% |
| Celyad Oncology SA | -8.44 Million EUR | -328.279% |
| DBV Technologies S.A. | -67.26 Million EUR | 46.215% |
| Galapagos NV | 211.69 Million EUR | 117.091% |
| Genfit S.A. | -28.89 Million EUR | -25.22% |
| GeNeuro SA | -14.75 Million EUR | -145.179% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -135.247% |
| Innate Pharma S.A. | -7.57 Million EUR | -377.952% |
| Inventiva S.A. | -110.42 Million EUR | 67.235% |
| MaaT Pharma SA | -19.71 Million EUR | -83.502% |
| MedinCell S.A. | -25.03 Million EUR | -44.504% |
| Nanobiotix S.A. | -39.7 Million EUR | 8.864% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -979.082% |
| OSE Immunotherapeutics SA | -23 Million EUR | -57.288% |
| Oxurion NV | -18.96 Million EUR | -90.738% |
| Pharming Group N.V. | -9.75 Million EUR | -270.837% |
| Poxel S.A. | -35.09 Million EUR | -3.109% |
| GenSight Biologics S.A. | -26.22 Million EUR | -37.99% |
| Transgene SA | -22.32 Million EUR | -62.043% |
| Financière de Tubize SA | 88.15 Million EUR | 141.044% |
| UCB SA | 343 Million EUR | 110.548% |
| Valneva SE | -101.42 Million EUR | 64.329% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | -27.659% |